Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis
PR98804
ANNAPOLIS, Md., Nov. 15, 2022 /PRNewswire=KYODO JBN/ --
Alphyn Biologics (
), a clinical-stage dermatology company developing first-in-class multi-target
therapeutics, announced today that it has completed the first cohort of its
Phase2a clinical trial of AB-101a, a topical therapeutic candidate for
mild-to-moderate atopic dermatitis (AD) in adults and children as young as 2
years old. The first cohort enrolled AD patients without bacterial infection,
which is sometimes associated with the disease. Top-line results are expected
in approximately eight weeks.
Logo -
The randomized, vehicle-controlled, double-blind trial is evaluating the
treatment protocol of AB-101a across multiple sites using standard scales for
assessing AD. Enrollment is ongoing in a second cohort of the trial, which
uniquely is investigating the treatment in AD patients who are also suffering
from bacterial infections, including staphylococcus aureus, or Staph, and MRSA,
the antibiotic-resistant Staph. Alphyn anticipates AB-101a will be effective
against non-infected AD and infected AD and expects it will offer patients and
physicians a comprehensive, safe, and convenient treatment option.
AB-101a was developed using Alphyn's proprietary AB-101 platform. The platform
has multiple bioactive compounds and, therefore, multiple mechanisms of action
to potentially address multiple problems of any target disease. Alphyn began
its clinical trial program in Phase 2 due to the strong safety profile of its
AB-101 platform.
ABOUT ALPHYN BIOLOGICS
Alphyn Biologics is a clinical-stage dermatology company developing
first-in-class multi-target therapeutics for severe and prevalent skin diseases
based on its AB-101 platform. Its lead product candidate, AB-101a, is being
developed as a topical treatment for atopic dermatitis (AD), the most common
form of eczema. AB-101a has demonstrated a strong safety profile and is in
development to uniquely target AD's immune system and bacterial components,
making it ideal for treating non-infected and infected AD. Alphyn's AB-101
platform has multiple bioactive compounds and therefore multiple mechanisms of
action to support a robust pipeline of dermatologic therapeutics that have
potential safety, efficacy and regulatory marketing authorization advantages.
Alphyn is based in Annapolis, Maryland and Cincinnati, Ohio, and has a wholly
owned Australia subsidiary. The company became operational in 2020 and has
raised approximately $6.9 million.
CONTACT: Corporate, Neal Koller, nkoller@alphynbiologics.com, (410) 690-8687;
Media, Susan Thomas, susan@endpointcommunications.net, (619) 540-9195
SOURCE: Alphyn Biologics
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
